ACB
Price
$5.59
Change
+$0.18 (+3.33%)
Updated
Jun 6, 12:30 PM (EDT)
Capitalization
238.86M
12 days until earnings call
SCYX
Price
$0.90
Change
+$0.01 (+1.12%)
Updated
Jun 6, 11:10 AM (EDT)
Capitalization
55.88M
73 days until earnings call
Interact to see
Advertisement

ACB vs SCYX

Header iconACB vs SCYX Comparison
Open Charts ACB vs SCYXBanner chart's image
Aurora Cannabis
Price$5.59
Change+$0.18 (+3.33%)
Volume$1K
Capitalization238.86M
SCYNEXIS
Price$0.90
Change+$0.01 (+1.12%)
Volume$800
Capitalization55.88M
ACB vs SCYX Comparison Chart
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. SCYX commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Buy and SCYX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (ACB: $5.41 vs. SCYX: $0.89)
Brand notoriety: ACB: Notable vs. SCYX: Not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ACB: 62% vs. SCYX: 76%
Market capitalization -- ACB: $238.86M vs. SCYX: $55.88M
ACB [@Pharmaceuticals: Other] is valued at $238.86M. SCYX’s [@Pharmaceuticals: Other] market capitalization is $55.88M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileSCYX’s FA Score has 0 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • SCYX’s FA Score: 0 green, 5 red.
According to our system of comparison, ACB is a better buy in the long-term than SCYX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 4 TA indicator(s) are bullish while SCYX’s TA Score has 5 bullish TA indicator(s).

  • ACB’s TA Score: 4 bullish, 5 bearish.
  • SCYX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, SCYX is a better buy in the short-term than ACB.

Price Growth

ACB (@Pharmaceuticals: Other) experienced а -2.05% price change this week, while SCYX (@Pharmaceuticals: Other) price change was -0.70% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +79.19%. For the same industry, the average monthly price growth was +16.15%, and the average quarterly price growth was +72.37%.

Reported Earning Dates

ACB is expected to report earnings on Aug 07, 2025.

SCYX is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+79.19% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACB($239M) has a higher market cap than SCYX($55.9M). ACB YTD gains are higher at: 27.224 vs. SCYX (-26.612). SCYX has higher annual earnings (EBITDA): 70.9M vs. ACB (-1.64B). ACB has more cash in the bank: 149M vs. SCYX (74.4M). SCYX has less debt than ACB: SCYX (15.1M) vs ACB (103M). ACB has higher revenues than SCYX: ACB (212M) vs SCYX (140M).
ACBSCYXACB / SCYX
Capitalization239M55.9M428%
EBITDA-1.64B70.9M-2,309%
Gain YTD27.224-26.612-102%
P/E RatioN/A1.06-
Revenue212M140M151%
Total Cash149M74.4M200%
Total Debt103M15.1M682%
FUNDAMENTALS RATINGS
ACB vs SCYX: Fundamental Ratings
ACB
SCYX
OUTLOOK RATING
1..100
155
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
56
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8994
PRICE GROWTH RATING
1..100
4282
P/E GROWTH RATING
1..100
7298
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCYX's Valuation (56) in the Pharmaceuticals Other industry is in the same range as ACB (58). This means that SCYX’s stock grew similarly to ACB’s over the last 12 months.

SCYX's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ACB (100). This means that SCYX’s stock grew similarly to ACB’s over the last 12 months.

ACB's SMR Rating (89) in the Pharmaceuticals Other industry is in the same range as SCYX (94). This means that ACB’s stock grew similarly to SCYX’s over the last 12 months.

ACB's Price Growth Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for SCYX (82). This means that ACB’s stock grew somewhat faster than SCYX’s over the last 12 months.

ACB's P/E Growth Rating (72) in the Pharmaceuticals Other industry is in the same range as SCYX (98). This means that ACB’s stock grew similarly to SCYX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBSCYX
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
N/A
Bullish Trend 1 day ago
73%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
N/A
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PRIDX70.57N/A
N/A
T. Rowe Price International Discovery
FIICX17.02N/A
N/A
Fidelity Advisor Mid Cap II C
SPVZX24.51N/A
N/A
PGIM Quant Solutions Mid-Cap Val Z
SSETX40.06N/A
N/A
BNY Mellon Small Cap Gr I
PRPAX5.90N/A
N/A
PGIM Jennison Energy Infrastructure A

SCYX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCYX has been loosely correlated with AQST. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if SCYX jumps, then AQST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCYX
1D Price
Change %
SCYX100%
-5.43%
AQST - SCYX
36%
Loosely correlated
+4.69%
CRON - SCYX
30%
Poorly correlated
-1.04%
ACB - SCYX
28%
Poorly correlated
-2.93%
TLRY - SCYX
27%
Poorly correlated
-5.40%
OGI - SCYX
27%
Poorly correlated
-2.24%
More